Psoriasis is a chronic, immune-mediated inflammatory skin disease
affecting 1.3–2.2% of the UK population.1 Most commonly, psoriasis is
characterised by well-demarcated, red plaques with adherent scale with a
predilection for the scalp and extensor surfaces of the limbs. However, the
effects of psoriasis go far beyond a patient’s skin and may result in a degree of
disability and impaired quality of life similar to that of other major medical
conditions, such as cancer and heart disease. First-line therapies for most